Results 201 to 210 of about 4,166,507 (358)

Harnessing Organoid Platforms for Nanoparticle Drug Development. [PDF]

Drug Des Devel Ther
Chen L, Luo X, Zhang J, Zhang J, Yang C, Zhao Y.   +5 more
europepmc   +1 more source

Drugs, Tsars and Economic Development [PDF]

, 1990
David W. Rasmussen
openalex   +1 more source

Drug Discovery and Development

JACS Au
Carole Duboc, Sabine L. Flitsch
openaire   +3 more sources

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development. [PDF]

Int J Toxicol
Pierson JB, Bahinski A, Berridge B, Bramham D, Bourcier T, Chaudhary KW, Eldridge S, Kanda Y, Mattes WB, Oliphant J, Pang L, Savtchenko A, Siegel J, Simpson N, Tu C, Wange R, Wu JC, Yang X.   +17 more
europepmc   +1 more source

Effects of Psychotropic Drugs on the Development of Activity-Stress Ulcer in Rats

, 1984
Chiaki Hara, Nobuya Ogawa
openalex   +1 more source

Obstacles to Clinical Research and New Drug Development in Schizophrenia [PDF]

, 1991
John M. Kane
openalex   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

Impact of Model-Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost. [PDF]

Clin Pharmacol Ther
Sahasrabudhe V, Nicholas T, Nucci G, Musante CJ, Corrigan B.   +4 more
europepmc   +1 more source

Strategies in the development of new drugs and drug combinations against leprosy, demonstrated on the example of folate and gyrase inhibitors

, 1986
J K Seydel, Myrna R. Rosenfeld, Manda Sathish, M. V. Wiese, K.-J. Schaper, G. HACHTEL, Ronald G. Haller, Manfred Kansy, A. M. Dhople   +8 more
openalex   +1 more source